Invention Grant
- Patent Title: Antisense oligonucleotides and their use for treating Pendred syndrome
-
Application No.: US17173864Application Date: 2021-02-11
-
Publication No.: US11312959B2Publication Date: 2022-04-26
- Inventor: Yimin Hua
- Applicant: ASOcura Pharmaceuticals Suzhou Co., Ltd.
- Applicant Address: CN Suzhou
- Assignee: ASOcura Pharmaceuticals Suzhou Co., Ltd.
- Current Assignee: ASOcura Pharmaceuticals Suzhou Co., Ltd.
- Current Assignee Address: CN Suzhou
- Agency: Perkins Coie LLP
- Main IPC: C12N15/113
- IPC: C12N15/113
Abstract:
The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that prevent or reduce exon 8 skipping in the SLC26A4 gene during pre-mRNA splicing, and their use in the treatment of Pendred Syndrome.
Public/Granted literature
- US20210246449A1 ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATING PENDRED SYNDROME Public/Granted day:2021-08-12
Information query
IPC分类:
